AUTL logo

AUTL
Autolus Therapeutics Ltd - ADR

3,636
Mkt Cap
$439.16M
Volume
676,250.00
52W High
$2.70
52W Low
$1.18
PE Ratio
-1.52
AUTL Fundamentals
Price
$1.74
Prev Close
$1.65
Open
$1.68
50D MA
$1.50
Beta
1.36
Avg. Volume
1.32M
EPS (Annual)
-$1.08
P/B
5.38
Rev/Employee
$100,484.27
$578.99
Loading...
Loading...
News
all
press releases
Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics Q1 Earnings Call Highlights...
News Placeholder
More News
News Placeholder
HC Wainwright Has Negative Outlook for AUTL Q2 Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Autolus Therapeutics in a note issued to investors on Thursday, April 30th. HC Wainwright analyst E. Bodnar now anticipates that the company wil...
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the company...
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday...
News Placeholder
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround
Autolus Therapeutics (NASDAQ:AUTL) is seeking to differentiate itself in the CAR-T market by pairing strong clinical activity with a safety profile that could allow broader patient access, CEO...
News Placeholder
HC Wainwright Issues Positive Outlook for AUTL Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Autolus Therapeutics...
News Placeholder
Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)
Needham & Company LLC restated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday...
News Placeholder
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicians and investigators who discussed the treatment landscape...
News Placeholder
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at Mizuho
Mizuho lowered their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available